Share on StockTwits

Equities researchers at ISI Group began coverage on shares of Mylan (NYSE:MYL) in a research report issued on Thursday. The firm set a “hold” rating on the stock.

A number of other analysts have also recently weighed in on MYL. Analysts at Leerink Swann cut their price target on shares of Mylan from $60.00 to $55.00 in a research note on Friday, August 8th. Separately, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Mylan in a research note on Friday, August 8th. They now have a $55.00 price target on the stock, down previously from $60.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Mylan in a research note on Friday, August 8th. They now have a $49.00 price target on the stock. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Mylan currently has a consensus rating of “Buy” and a consensus price target of $54.45.

Shares of Mylan (NYSE:MYL) traded down 1.82% on Thursday, hitting $46.94. The stock had a trading volume of 4,654,183 shares. Mylan has a 52 week low of $34.86 and a 52 week high of $57.52. The stock has a 50-day moving average of $48.76 and a 200-day moving average of $49.91. The company has a market cap of $17.558 billion and a price-to-earnings ratio of 32.55.

Mylan (NYSE:MYL) last released its earnings data on Thursday, August 7th. The company reported $0.69 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.73 by $0.04. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company posted $0.68 earnings per share. The company’s quarterly revenue was up 7.9% on a year-over-year basis. Analysts expect that Mylan will post $3.29 EPS for the current fiscal year.

Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.